J Endocrinol Metab

Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access

Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc

Journal website https://www.jofem.org

Original Article

Volume 10, Number 3-4, August 2020, pages 89-93

Sodium-Glucose Co-Transporter 2 Inhibitors Increase Serum Level of Total Procollagen Type 1 Amino-Terminal Propeptide and Bone Strength in Japanese Patients With Type 2 Diabetes Mellitus

**Table 1.** Characteristics of Patients Enrolled in the Study
Data are expressed as mean ± SD. SD: standard deviation; BMI: body mass index; HbA1c: hemoglobin A1c; DPP4: dipeptidyl peptidase 4.
Number of patients	19
Male/female	16/3
Age (years)	66 ± 12
Body weight(kg)	73.7 ± 10.9
BMI (kg/m²)	26.6 ± 3.2
HbA1c (%)	7.4 ± 1.1
Concomitant medication
Anti-diabetic drug (n)
Biguanide	6
Sulfonylurea	1
Insulin	1
Alpha-glucosidase inhibitor	5
Thiazolidinedione	3
DPP4-inhibitor	10
Lipid-modifying agents (n)	13
Antihypertensive drug (n)	13

Table 1. Characteristics of Patients Enrolled in the Study

Data are expressed as mean ± SD. SD: standard deviation; BMI: body mass index; HbA1c: hemoglobin A1c; DPP4: dipeptidyl peptidase 4.

Number of patients

Male/female

16/3

Age (years)

66 ± 12

Body weight(kg)

73.7 ± 10.9

BMI (kg/m²)

26.6 ± 3.2

HbA1c (%)

7.4 ± 1.1

Concomitant medication

Anti-diabetic drug (n)

Biguanide

Sulfonylurea

Insulin

Alpha-glucosidase inhibitor

Thiazolidinedione

DPP4-inhibitor

Lipid-modifying agents (n)

Antihypertensive drug (n)

**Table 2.** Effects of Six Months’ Administration of SGLT2 Inhibitors on the Body Weight, BMI, HbA1c, and Glucose- and Lipid-Metabolic Parameters
	Before administration	After 6 months’ administration
Data are expressed as mean ± SD. P < 0.05, *P < 0.01 vs. before administration. SD: standard deviation; BMI: body mass index; HbA1c: hemoglobin A1c; SGLT2: sodium-glucose co-transporter 2; LDL: low-density lipoprotein; HDL: high-density lipoprotein.
Body weight (kg)	73.7 ± 10.9	70.6 ± 11.2**
BMI (kg/m²)	26.6 ± 3.2	25.5 ± 3.2**
HbA1c (%)	7.4 ± 1.1	6.8 ± 0.8*
Blood glucose (mg/dL)	115 ± 36	98 ± 17*
Serum total cholesterol (mg/dL)	190 ± 30	187 ± 23
Serum LDL-cholesterol (mg/dL)	112 ± 26	111 ± 20
Serum HDL-cholesterol (mg/dL)	52 ± 10	59 ± 9**
Serum triglyceride (mg/dL)	186 ± 94	117 ± 67**

Table 2. Effects of Six Months’ Administration of SGLT2 Inhibitors on the Body Weight, BMI, HbA1c, and Glucose- and Lipid-Metabolic Parameters

Before administration

After 6 months’ administration

Data are expressed as mean ± SD. *P < 0.05, **P < 0.01 vs. before administration. SD: standard deviation; BMI: body mass index; HbA1c: hemoglobin A1c; SGLT2: sodium-glucose co-transporter 2; LDL: low-density lipoprotein; HDL: high-density lipoprotein.

Body weight (kg)

73.7 ± 10.9

70.6 ± 11.2**

BMI (kg/m²)

26.6 ± 3.2

25.5 ± 3.2**

HbA1c (%)

7.4 ± 1.1

6.8 ± 0.8*

Blood glucose (mg/dL)

115 ± 36

98 ± 17*

Serum total cholesterol (mg/dL)

190 ± 30

187 ± 23

Serum LDL-cholesterol (mg/dL)

112 ± 26

111 ± 20

Serum HDL-cholesterol (mg/dL)

52 ± 10

59 ± 9**

Serum triglyceride (mg/dL)

186 ± 94

117 ± 67**

**Table 3.** Effects of Six Months’ Administration of SGLT2 Inhibitors on Bone Strength, Bone Density and Bone Metabolism-Related Parameters
	Before administration	After 6 months’ administration
Data are expressed as mean ± SD. *P < 0.05 vs. before administration. Bone strength and density are expressed as the comparison with those in young adult means. QUS: quantitative ultrasound; DEXA: dual-energy X-ray absorptiometry; SD: standard deviation; SGLT2: sodium-glucose co-transporter 2.
Bone strength measured by QUS
Calcaneal bone (%)	88 ± 16	91 ± 15*
Bone density measured by DEXA
Lumbar spine (%)	109 ± 13	106 ± 12
Femur (%)	87 ± 13	83 ± 10
Serum total P1NP (µg/L)	35.2 ± 10.3	39.0 ± 12.8*
Serum TRACP-5b (mU/dL)	215 ± 62	245 ± 82

Table 3. Effects of Six Months’ Administration of SGLT2 Inhibitors on Bone Strength, Bone Density and Bone Metabolism-Related Parameters

Before administration

After 6 months’ administration

Data are expressed as mean ± SD. *P < 0.05 vs. before administration. Bone strength and density are expressed as the comparison with those in young adult means. QUS: quantitative ultrasound; DEXA: dual-energy X-ray absorptiometry; SD: standard deviation; SGLT2: sodium-glucose co-transporter 2.

Bone strength measured by QUS

Calcaneal bone (%)

88 ± 16

91 ± 15*

Bone density measured by DEXA

Lumbar spine (%)

109 ± 13

106 ± 12

Femur (%)

87 ± 13

83 ± 10

Serum total P1NP (µg/L)

35.2 ± 10.3

39.0 ± 12.8*

Serum TRACP-5b (mU/dL)

215 ± 62

245 ± 82